DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Turalio is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are eleven patents protecting this drug.
This drug has one hundred and sixteen patent family members in forty-one countries.
The generic ingredient in TURALIO is pexidartinib hydrochloride. One supplier is listed for this compound. Additional details are available on the pexidartinib hydrochloride profile page.
Turalio will be eligible for patent challenges on August 2, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 24, 2038. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for turalio
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||52|
|Drug Prices:||Drug price information for turalio|
|What excipients (inactive ingredients) are in turalio?||turalio excipients list|
|DailyMed Link:||turalio at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for turalio
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|China||107548394||Get Started Free|
|Eurasian Patent Organization||201491721||Get Started Free|
|South Korea||20200032683||Get Started Free|
|Japan||6165837||Get Started Free|
|Denmark||3292123||Get Started Free|
|South Korea||20200139832||Get Started Free|
|>Country||>Patent Number||>Estimated Expiration|